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MetMethods
Discussion
• Detection of  HSP70, TSG101, and CD9 for size 
exclusion chromatography (SEC) sample indicates 
the presence of exosomes.
• Although ExoQuick Plus removed more albumins 
than SEC, only a weak signal of exosomal marker 
HSP70 was observed for ExoQuick Plus sample.
• A greater number of particles within the size range 
of exosome was observed for ExoQuick Plus than 
that of SEC. However, the lack of signals for 
TSG101 and CD9 for ExoQuick Plus may indicate 
the presence of co-isolated lipoproteins, which 
share similar size range with exosomes.4
• Since NTA does not distinguish exosomes from 
other particles of similar size, transmission 
electron microscopy is recommended to confirm 
the NTA results and the presence of lipoproteins.4,5
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Conclusion
• SEC enriched exosomes with all three exosomal
markers found to be positive, but was 
contaminated with albumins. 
• ExoQuick Plus removed highly-abundant protein 
albumins.  
• We will use 100 kDa centrifugal filter device to 
remove albumins from SEC samples for future 
experiments and further characterize exosomes 
using transmission electron microcopy and mass-
spectrometry.
Introduction
• Sarcoidosis is a systemic granulomatous disease of unknown cause, with highly variable manifestation and disease 
course.1
• Currently, no specific and sensitive  biomarkers for diagnosis and prognosis in sarcoidosis are available for routine 
clinical use.2
• Exosomes are extracellular vesicles ranged from 30-100 nm in size and involved in cell-to-cell communication through 
the delivery of cargo that may contain potential disease biomarkers.3
• We hypothesized that characterizing the exosomal cargo will provide novel insights into the disease mechanism and 
biomarkers in sarcoidosis. 
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Objectives
• Our long-term goal is to identify organ-specific sarcoidosis-related pathways for precise therapy. 
• For this UROP project, we developed methods to obtain and characterize exosomes from human plasma with the 
following aims: 
1) Compare the efficiency of size exclusion chromatography (SEC) and ExoQuick Plus in isolating exosomes 
2) Use Western blot and nanoparticle tracking analysis (NTA) to assess the quality of the isolated exosomes.
Results
Figure 1: Characterization of the isolated exosomes by Western Blot. 
11ug of proteins were loaded for all samples. HSP70, TSG101, and CD9 
were used as exosomal markers, while albumin was used as a 
contamination marker. 
Figure 2: Characterization of the isolated exosomes by nanoparticle 
tracking analysis (NTA). Size exclusion chromatography yielded a modal 
size of 118 nm (A), while ExoQuick Plus yielded a modal size of 103 nm 
(B), with size distribution of 1.27x1011 particles/mL and 2.96x1011
particles/mL, respectively, for all particles ranged from 30-1000 nm (C).
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Methods
Addition of 1 mL of plasma 
into a column containing 
Sepharose CL-2B beads and 
pre-treated with elution buffer
Addition of elution buffer 
to the column. 
Discard the first 2 mL 
of eluate. 
Fraction 1, 2, 3, 4, 5
Collection 5 
fractions of 1 
mL each
Run the 
column.
Analysis
• Western Blot
• Nanoparticle 
Tracking Analysis 
Size Exclusion 
Chromatography
Addition of 250 uL of  
thrombin-treated plasma 
into a tube containing 
ExoQuick Precipitation 
Solution
30 min 
spin,
1500 x g
Resuspension of 
exosomal pellet.
Transfer 500 ug of protein 
to ExoQuick Plus 
Microsphere beads
Mix for 15 min, 
then 30 min 
spin, 1500 x g
Supernatant
ExoQuick
ExoQuick Plus 
ExoQuick Plus
Future Study
• Transmission 
electron microscopy
• Mass-spectrometry
ethods
